<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="30602" end="30607" sStart="30574" offset="28" sid="r7.1.use.v.0997" wn="1" wnkey="use%2:34:01::" annotator="veweser" text="Wilcoxon test was performed using NPAR1WAY procedure in SAS, stepwise discriminant analysis was performed using STEPDISC procedure in SAS, and discriminant analysis was performed using DISCRIM procedure in SAS [ 23 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="12077" end="12081" sStart="null" offset="50" sid="r7.1.use.v.0248" wn="1" wnkey="use%2:34:01::" annotator="cgozo" text="We have used a strategy identical to that used in Rule 1 to further analyze this data." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-4-24.anc" start="22408" end="22414" sStart="null" offset="0" sid="null" wn="1" wnkey="try%2:41:00::" annotator="comcgeetubb" text="Another group &lt;b&gt;trying&lt;/b&gt; to repeat the observations of increased levels of LPA associated with ovarian cancer concluded that there was no diagnostic value in the assay, and attributed the discrepant findings as possibly related to different sample centrifugation protocols used by the two groups to remove platelets from the samples prior to analysis [ 20 ] . However, LPA continues to be actively evaluated for its clinical utility [ 21 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="24191" end="24198" sStart="null" offset="37" sid="r8.suggest.v.0587" wn="3" wnkey="suggest%2:32:02::" annotator="brubin" text="In particular these preliminary data suggest that these two rules may be specific enough to scale to larger population trials without generating an unacceptably high false positive rate." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2105-4-24.anc" start="19389" end="19394" sStart="null" offset="0" sid="null" wn="5" wnkey="show%2:36:00::" annotator="elstickles" text="This report also reviews the evidence that these M/Z values are consistent with LPA family members [ 19 ] . Figure 4&lt;b&gt;shows&lt;/b&gt; the average intensities and p-values for both the cancer and control groups in the region between M/Z values of 410 to 470." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2105-4-24.anc" start="19389" end="19394" sStart="null" offset="0" sid="null" wn="4" wnkey="show%2:39:00::" annotator="comcgeetubb" text="This report also reviews the evidence that these M/Z values are consistent with LPA family members [ 19 ] . Figure 4&lt;b&gt;shows&lt;/b&gt; the average intensities and p-values for both the cancer and control groups in the region between M/Z values of 410 to 470." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2105-4-24.anc" start="19389" end="19394" sStart="null" offset="0" sid="null" wn="5" wnkey="show%2:36:00::" annotator="cgozo" text="This report also reviews the evidence that these M/Z values are consistent with LPA family members [ 19 ] . Figure 4&lt;b&gt;shows&lt;/b&gt; the average intensities and p-values for both the cancer and control groups in the region between M/Z values of 410 to 470." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2105-4-24.anc" start="19389" end="19394" sStart="null" offset="0" sid="null" wn="5" wnkey="show%2:36:00::" annotator="carichter" text="This report also reviews the evidence that these M/Z values are consistent with LPA family members [ 19 ] . Figure 4&lt;b&gt;shows&lt;/b&gt; the average intensities and p-values for both the cancer and control groups in the region between M/Z values of 410 to 470." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2105-4-24.anc" start="19389" end="19394" sStart="null" offset="0" sid="null" wn="5" wnkey="show%2:36:00::" annotator="carichter" text="This report also reviews the evidence that these M/Z values are consistent with LPA family members [ 19 ] . Figure 4&lt;b&gt;shows&lt;/b&gt; the average intensities and p-values for both the cancer and control groups in the region between M/Z values of 410 to 470." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2105-4-24.anc" start="19389" end="19394" sStart="null" offset="0" sid="null" wn="5" wnkey="show%2:36:00::" annotator="brubin" text="This report also reviews the evidence that these M/Z values are consistent with LPA family members [ 19 ] . Figure 4&lt;b&gt;shows&lt;/b&gt; the average intensities and p-values for both the cancer and control groups in the region between M/Z values of 410 to 470." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="25067" end="25077" sStart="null" offset="3" sid="r10.particular.j.0177" wn="2147483647" wnkey="null" annotator="veweser" text="In particular, if experimental bias and noise effects can be excluded, this region may prove to offer the optimum for ovarian cancer diagnostic test development." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="26695" end="26705" sStart="null" offset="3" sid="r10.particular.j.0880" wn="2147483645" wnkey="null" annotator="brubin" text="In particular the coagulation and complement systems should be considered as potential sources of noise in this context, as both are activated during serum sample collection and generate low molecular weight products." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="24157" end="24167" sStart="null" offset="3" sid="r10.particular.j.0750" wn="3" wnkey="particular%5:00:00:uncommon:00" annotator="anfahmy" text="In particular these preliminary data suggest that these two rules may be specific enough to scale to larger population trials without generating an unacceptably high false positive rate." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="9328" end="9334" sStart="null" offset="135" sid="r9.normal.j.0941" wn="1" wnkey="normal%3:00:01::" annotator="veweser" text="Thirteen M/Z values were retained in Rule 2. In the training set, one subject in the cancer group was misclassified as normal and one in the control group was misclassified as cancer." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="25985" end="25991" sStart="null" offset="178" sid="r9.normal.j.0404" wn="1" wnkey="normal%3:00:01::" annotator="brubin" text="Also, the possibility that the changes in the low M/Z region may represent an additive effect caused by differing protein environments between cancer and normal may be approached by intentionally spiking samples with panels of known proteins, and determining if there is an effect on the spectra in the low M/Z region." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="15468" end="15475" sStart="null" offset="37" sid="r10.find.v.0890" wn="2147483645" wnkey="null" annotator="anfahmy" text="Even more interesting is the finding that significant M/Z values found in the first Rule 1 included the M/Z values of 2.7921478 and 245." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="12875" end="12884" sStart="null" offset="107" sid="r8.1.different.j.0245" wn="2" wnkey="different%5:00:00:other:00" annotator="veweser" text="Each sheet contains the most significant 100 MZ values from a training set consisting of a different 80% subset of the data." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="13914" end="13921" sStart="null" offset="111" sid="r10.control.n.0817" wn="4" wnkey="control%1:09:02::" annotator="veweser" text="For example 3,591 of the 15,154 M/Z values had mean intensities that varied between cancer and control with a p-value of 10 -6or less." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="6891" end="6899" sStart="null" offset="343" sid="r10.control.n.0931" wn="4" wnkey="control%1:09:02::" annotator="cgozo" text="Based on the initial training set, the intensity at each of the consecutive 15,154 M/Z values was first compared using a two-sided Wilcoxon test (see methods) Figure 1shows the pattern of the resulting two-sided Wilcoxon test p-values generated on a training set consisting of 80 cancer patients and 45 controls randomly chosen from the larger data set, with the M/Z values on the x-axis and the negative logarithm (base 10) of the Wilcoxon test p-values on the y-axis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="4908" end="4915" sStart="null" offset="299" sid="r10.control.n.0202" wn="4" wnkey="control%1:09:02::" annotator="anfahmy" text="Further, we use Wilcoxon test and stepwise discriminant analysis on a training subset consisting of 80 cancer patients and 45 controls, randomly chosen from the original data set, to develop rules to classify a test set consisting of the remaining cancer and control subjects." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="21050" end="21056" sStart="null" offset="164" sid="r10.common.j.0210" wn="3" wnkey="common%5:00:00:shared:00" annotator="anfahmy" text="For example, if a set of proteins exist that are expressed at different levels between cancer and control subjects but have a common domain, then a common product ion of lower M/Z may be generated that would represent a summation of all the changes in expression of the group of proteins, and might thus have greater statistical significance than the changes associated with any single high M/Z value." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="28113" end="28124" sStart="null" offset="12" sid="r11.combination.n.0766" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="Any combination of such steps may significantly alter the molecular subset of the sample that can be successfully analyzed." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2105-4-24.anc" start="18948" end="18959" sStart="null" offset="656" sid="r11.combination.n.0272" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="Lysophophatidic Acid (LPA) is a member of this class of compounds, and its plasma levels have been proposed as a potential biomarker for ovarian cancer [ 16 17 ] . LPA is a family of related molecules with molecular weights in the vicinity of 400 to 600 Daltons, and a variety of LPA species has been reported to be increased in malignant ascites from patients with ovarian cancer as detected by electrospray ionization mass spectrometry (ESI-MS) [ 18 ] . LPA related species have also been reported to be increased in plasma samples from patients with ovarian cancer using a combination of thin layer chromatography (to isolate an &quot;LPA band&quot; from patient plasma) followed by ESI-MS." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-4-24.anc" start="14314" end="14320" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="tofox" text="Alternatively, in the above setting the &lt;b&gt;chance&lt;/b&gt; that at least one of the 15,154 measurements would have a p-value less than 10 -6is approximately 1.5%." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-4-24.anc" start="16878" end="16884" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="tofox" text="Thus, it is highly unlikely that either data normalization or a &lt;b&gt;chance&lt;/b&gt; distribution could have accounted for the highly significant p-values noted in the M/Z region less than 500." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-4-24.anc" start="14516" end="14522" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="tofox" text="Thus it is extremely unlikely that a false positive would occur by &lt;b&gt;chance&lt;/b&gt; alone in a 15,154 member test set." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-4-24.anc" start="14314" end="14320" sStart="null" offset="0" sid="null" wn="4" wnkey="chance%1:07:00::" annotator="comcgeetubb" text="Alternatively, in the above setting the &lt;b&gt;chance&lt;/b&gt; that at least one of the 15,154 measurements would have a p-value less than 10 -6is approximately 1.5%." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-4-24.anc" start="16878" end="16884" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="comcgeetubb" text="Thus, it is highly unlikely that either data normalization or a &lt;b&gt;chance&lt;/b&gt; distribution could have accounted for the highly significant p-values noted in the M/Z region less than 500." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-4-24.anc" start="14516" end="14522" sStart="null" offset="0" sid="null" wn="2" wnkey="chance%1:19:00::" annotator="comcgeetubb" text="Thus it is extremely unlikely that a false positive would occur by &lt;b&gt;chance&lt;/b&gt; alone in a 15,154 member test set." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-4-24.anc" start="14314" end="14320" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="chisom" text="Alternatively, in the above setting the &lt;b&gt;chance&lt;/b&gt; that at least one of the 15,154 measurements would have a p-value less than 10 -6is approximately 1.5%." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-4-24.anc" start="16878" end="16884" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="chisom" text="Thus, it is highly unlikely that either data normalization or a &lt;b&gt;chance&lt;/b&gt; distribution could have accounted for the highly significant p-values noted in the M/Z region less than 500." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2105-4-24.anc" start="14516" end="14522" sStart="null" offset="0" sid="null" wn="" wnkey="null" annotator="chisom" text="Thus it is extremely unlikely that a false positive would occur by &lt;b&gt;chance&lt;/b&gt; alone in a 15,154 member test set." />
  </sentences>
</list>